Inclusion Criteria:

- Fourth stage Melanoma patients with both measurable and not measurable lesions
undergoing treatment with selective B-RAF inhibitors will be included. To determine
the prevalence of CMC-positive patients in IV stage Melanoma, patients without
mutated B-RAF undergoing chemotherapy and/or vaccines will be also enrolled at
baseline, as part of study protocols approved and activated in the participating
centers.

- Informed written consent.

Exclusion Criteria:

- Inadequate compliance to multiple blood draws (baseline, 15 days, 1th month, 4th
month, and/or at progression) as scheduled in this adjunctive biologic study for
patients carrying B-FAF mutation; inadequate compliance to adjunctive blood draws, as
scheduled at baseline for BRAF wild-type

- Previously exposure to immunological treatment.